Long-Term Safety of ARQ-154 Foam in Subjects With Seborrheic Dermatitis
NCT04445987
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
408
Enrollment
INDUSTRY
Sponsor class
Conditions
Seborrheic Dermatitis
Interventions
DRUG:
ARQ-154
Sponsor
Arcutis Biotherapeutics, Inc.